Very Late Stent Thrombosis: The Value of Optical Coherence Tomography in Defining Etiology and Guiding Treatment

Can J Cardiol. 2016 Jun;32(6):830.e9-830.e10. doi: 10.1016/j.cjca.2015.08.008. Epub 2015 Aug 15.

Authors

Liam Mullen¹, Aleem Khand²

Affiliations

¹ Liverpool Heart and Chest Hospital, NHS Foundation Trust, Liverpool, United Kingdom; University Hospital Aintree, NHS Foundation Trust, Liverpool, United Kingdom. Electronic address: liammullen@nhs.net.
² Liverpool Heart and Chest Hospital, NHS Foundation Trust, Liverpool, United Kingdom; University Hospital Aintree, NHS Foundation Trust, Liverpool, United Kingdom; University of Liverpool, Liverpool, United Kingdom.

PMID: 26514750
DOI: 10.1016/j.cjca.2015.08.008

No abstract available

Publication types

Case Reports

MeSH terms

Abciximab
Antibodies, Monoclonal / administration & dosage*
Coronary Restenosis / diagnosis
Coronary Restenosis / drug therapy
Coronary Restenosis / etiology
Coronary Restenosis / physiopathology
Coronary Thrombosis / diagnosis
Coronary Thrombosis / drug therapy
Coronary Thrombosis / etiology
Coronary Thrombosis / physiopathology
Coronary Vessels / diagnostic imaging*
Drug-Eluting Stents / adverse effects
Humans
Immunoglobulin Fab Fragments / administration & dosage*
Injections, Intra-Arterial / methods
Long Term Adverse Effects* / diagnosis
Long Term Adverse Effects* / drug therapy
Long Term Adverse Effects* / etiology
Long Term Adverse Effects* / physiopathology
Male
Middle Aged
Non-ST Elevated Myocardial Infarction / surgery*
Percutaneous Coronary Intervention* / adverse effects
Percutaneous Coronary Intervention* / instrumentation
Percutaneous Coronary Intervention* / methods
Platelet Aggregation Inhibitors / administration & dosage
Tomography, Optical Coherence / methods*
Treatment Outcome

Substances

Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Abciximab